Jasper Therapeutics, Inc. (JSPR)

Jasper Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	28.69	71.64	86.89	38.25	84.7
Cash & Short-Term Investments	28.69	71.64	86.89	38.25	84.7
Cash Growth	-59.95%	-17.55%	127.16%	-54.84%	326.96%
Other Receivables	-	-	-	0.66	-
Total Trade Receivables	-	-	-	0.66	-
Other Current Assets	5.95	4.17	2.05	2.82	3.13
Total Current Assets	34.65	75.81	88.94	41.73	87.83
Net Property, Plant & Equipment	0.6	2.85	4.19	5.45	4.83
Other Long-Term Assets	0.53	1.24	1.76	1.18	0.99
Total Assets	35.78	79.9	94.89	48.36	93.65
Accounts Payable	6.22	4.03	4.15	1.77	3.92
Accrued Expenses	5.75	10.12	7.25	4.43	3.6
Current Portion of Leases	1.24	1.09	0.97	0.87	0.51
Total Current Liabilities	13.2	15.24	12.37	7.07	8.02
Long-Term Leases	-	0.72	1.81	2.79	2.38
Other Long-Term Liabilities	18.43	2.26	2.26	2.52	13.74
Total Long-Term Liabilities	18.43	2.99	4.08	5.31	16.12
Total Liabilities	31.63	18.23	16.45	12.37	24.14
Common Stock	0	0	0	0	0
Additional Paid-in Capital	320.82	302.54	248.04	141.12	136.96
Retained Earnings	-316.67	-240.87	-169.6	-105.14	-67.45
Total Common Shareholders' Equity	4.15	61.67	78.44	35.99	69.52
Shareholders' Equity	4.15	61.67	78.44	35.99	69.52
Total Liabilities & Equity	35.78	79.9	94.89	48.36	93.65
Total Debt	1.24	1.81	2.79	3.65	2.89
Net Cash (Debt)	27.46	69.82	84.1	34.6	81.82
Net Cash Growth	-60.68%	-16.98%	143.07%	-57.71%	349.19%
Net Cash Per Share	1.43	4.79	8.06	9.48	71.81
Book Value	4.15	61.67	78.44	35.99	69.52
Book Value Per Share	0.22	4.23	7.51	9.87	61.01
Tangible Book Value	4.15	61.67	78.44	35.99	69.52
Tangible Book Value Per Share	0.22	4.23	7.51	9.87	61.01

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q